Applications for the 2023 Henri Termeer Transatlantic Connections Award are currently being accepted until Friday January 6th. Please find the nomination form here.


The 2022 Henri Termeer Transatlantic Connections Award honorees were: Kasper Roet, CEO and co-founder of, QurAlis Corporation; and Koenraad Wiedhaup, CEO and founder of Leyden Labs.

images/news/kasperroet_375.jpg

Kasper Roet

QurAlis Corporation

Kasper Roet
images/news/koenraad_375.jpg

Koenraad Wiedhaup

Leyden Labs

Koenraad Wiedhaup

 

 

 ~ Kasper Roet, PhD, is CEO and co-founder of QurAlis Corporation. He is also co-founder and serves on the board of directors of EnClear Therapies. Kasper is a passionate neuroscientist and therapy developer who specializes in gene therapies and stem cell technology-based precision medicine solutions for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Kasper’s work at the Netherlands Brain Bank emphasized the need for effective treatments for patients and their families. Upon seeing the incredible achievements in stem cell modeling and gene discoveries in ALS, Kasper realized that this is the time to make a real difference for patients.

He decided to move to Boston from the Netherlands with his wife, and work with two visionary leaders in ALS stem cell disease modeling, Harvard professors Clifford Woolf and Kevin Eggan with whom he co-founded QurAlis to bring breakthrough precision therapies for ALS and other neurodegenerative diseases. Kasper was trained by industry thought leaders at Johnson and Johnson along with forward-thinking scientific and business thought leaders at Harvard University. Kasper obtained his PhD degree at the Netherlands Institute for Neuroscience and the Free University of Amsterdam and obtained a master’s degree with honors from the University of Amsterdam. Kasper was awarded the Milton Safenowitz postdoctoral fellowship from the ALS Association. With QurAlis, Kasper won two Golden Tickets (Amgen 2017 and Pfizer 2018), became a JLabs member in 2018, and won the Fierce15 Biotech award in 2020.

 ~ Koenraad Wiedhaup is a founder and the CEO of Leyden Labs, a biotech company that aims to free people from the threat of viruses by developing mucosal products. He is committed to helping people strive for a fantastic life by bringing scientific developments to those who need them.

Before his current role, he was a Partner with McKinsey & Company’s Life Science practice where he advised pharmaceutical, biotech and medtech companies throughout Europe and the US.

Koenraad has a background in Science, studying Life Sciences and Biotechnology at the Universities of Leiden and Delft and in Business, with an MBA from Columbia Business School in New York. Koenraad started his career at a biotech company in the San Francisco Bay Area.


The 2021 Henri Termeer Transatlantic Connections Award honorees were: Eline van Beest, CEO, Hybridize Therapeutics; and Joshua Cohen and Justin Klee, co-Founders and co-CEOs of Amylyx Pharmaceuticals.

images/news/elinevanbeest_300.jpg

Eline van Beest

Hybridize Therapeutics

Eline van Beest
images/news/joshuacohen_300.jpg

Joshua Cohen

Amylyx Pharmaceuticals

Joshua Cohen
images/news/justinklee_300.jpg

Justin Klee

Amylyx Pharmaceuticals

Justin Klee

~  Eline van Beest is CEO of Hybridize Therapeutics, an early-stage Dutch biotechnology company focused on developing virus-specific RNA-based therapies. She has a technical background with a Masters degree in Industrial Design Engineering (Delft University of Technology, Cum Laude), and has further education in business innovation and coaching. She is CEO of Hybridize Therapeutics, an early-stage Dutch biotechnology company focused on developing virus-specific RNA-based therapies. She is also the founder and CEO of NightBalance, a leading innovator of obstructive sleep apnea (OSA) technology. While building the venture, Eline gained experience in medical product development, international clinical trials, getting reimbursement coding, filing and protecting Intellectual Property, commercializing a medical innovation, fundraising and building teams and medical advisory boards. NightBalance was acquired by Philips in May 2018.

Also, Eline holds a position as a member of the Supervisory Board of Livassured, a company that introduces a smart wearable that warns caretakers on epileptic seizures. Eline was nominated for several lists of female and/or tech entrepreneurs like amongst others the Rising Star at the World Women’s Forum and 35 Innovators Under 35 by MIT.

~ Justin Klee and Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013. Today, they serve as co-CEOs and have overseen the development of an investigational product for ALS and Alzheimer’s disease by working with top hospitals and investigators around the country, raising over $100,000,000 in funding and overseeing all preclinical, regulatory and clinical operations and strategy to bring AMX0035 through clinical trials.

Josh and Justin have built a team of industry leaders, rapidly growing the company to over 30 full time employees in recent years. In 2020, the company announced the detailed CENTAUR trial results that were published in the New England Journal of Medicine (NEJM), which showed a significant slowing in ALS disease progression compared to placebo, providing hope for people with ALS.

Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School and received his Sc.B in Neuroscience from Brown University, while Josh’s research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BSE in biomedical engineering from Brown University. In 2019, Josh and Justin won Xconomy’s Young Innovator Award and in 2020 were named to Business Insider’s 30 under 40 in health care list and PM360’s Elite in the Drug Researchers and Developers Category. Amylyx was also selected as one of Fierce Biotech’s 2020 Fierce 15 companies.


 

termeer logo bottom